Oncologists must be prepared to inform patients about risks, benefits of CAR T-cell therapies – Healio
|
Oncologists must be prepared to inform patients about risks, benefits of CAR T-cell therapies
Healio Porter, who gave an update of chimeric antigen receptor (CAR) T-cell therapies, said he felt it was necessary to explain the excitement surrounding the recent FDA approval of tisagenlecleucel T-suspension (Kymriah, Novartis) for the treatment of … |
